TETRAXIM
Suspension for Injection 1's
registration number
A38/30.1/0526
What TETRAXIM is and what it is used for
TETRAXIM is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis:
• For primary vaccination in infants.
• For booster vaccination in children who have previously received a primary vaccination with this vaccine or a diphtheria-tetanus-whole cell or acellular pertussis-poliomyelitis vaccine.
dosage
Primary vaccination:
Starting from 6 weeks of age, the three-dose primary vaccination is three successive doses of 0,5 mL given at an interval of one or two months, such as 6, 10 and 14 weeks or 2, 3, 4 months or 2, 4, 6 months or 3, 4, 5 months or 3, 5, 12 months (or according to national vaccination policies).
Booster vaccination:
A fourth dose should be administered within the second year of life in children who received TETRAXIM (or a diphtheria-tetanus-whole cell or acellular pertussis-poliomyelitis vaccine, whether mixed or not with the freeze-dried conjugate Haemophilus influenzae type b vaccine) as a three-dose primary series.
Late booster:
1 booster injection at 5 – 12 years old in children who were previously immunised with an acellular vaccine (3 or 4 doses) or 3 doses of a whole cell vaccine followed by a booster dose of either acellular or whole cell vaccine. Booster doses in 5 through 12 years old individuals should be given in accordance with the official national vaccination policies.
how to take
Before injection, shake to obtain a homogenous whitish-turbid suspension.
This vaccine must be administered intramuscularly. The intradermal or intravenous routes must not be used. The recommended injection sites are the antero-lateral aspect of the upper thigh in infants and the deltoid muscle in older children.
The vaccine must neither be mixed with other medical products, except Act-HIB vaccine, nor with other substances for parenteral use.
What TETRAXIM contains
Purified diphtheria toxoid(1) ≥ 30 IU(2,3)
Purified tetanus toxoid(1) ≥ 40 IU(3,4)
Purified pertussis toxoid (PTxd)(1) 25 micrograms
Purified pertussis filamentous haemagglutinin (FHA)(1) 25 micrograms
Inactivated type 1 poliovirus (Mahoney)(5) D antigen 40 units(6)
Inactivated type 2 poliovirus (MEF1)(5) D antigen 8 units(6)
Inactivated type 3 poliovirus (Saukett)(5) D antigen 32 units(6)
(1) Adsorbed on aluminium hydroxide, hydrated (0,3 mg Al3+)
(2) As mean value
(3) Or equivalent activity determined by an immunogenicity evaluation
(4) As lower confidence limit (p = 0,95)
(5) Produced on VERO cells
(6) Or equivalent antigenic quantity determined by a suitable immunochemical method.
other ingredients
Aluminium hydroxide (expressed as Al3+)
Ethanol anhydrous (as preservative)
Formaldehyde (as preservative)
Medium 199 Hanks’ 10 x C without phenol red
Phenoxyethanol (as preservative)
Acetic acid glacial and/or sodium hydroxide (for pH adjustment)
Water for injection.
The 10 x C Medium 199 Hanks’ (without phenol red) is a complex mixture of amino acids (including phenylalanine), mineral salts, vitamins and other components (such as glucose) diluted in water for injections.
During manufacture of the poliomyelitis valence, polymyxin B, glutaraldehyde, streptomycin and neomycin are used and traces may remain in the final vaccine.
Therapeutic classification
J07CA02.